Recursos de colección

PubMed Central (PMC3 - NLM DTD) (2.997.259 recursos)

Archive of life sciences journal literature at the U.S. National Institutes of Health (NIH), developed and managed by NIH's National Center for Biotechnology Information (NCBI) in the National Library of Medicine (NLM).

Clinical Epigenetics

Mostrando recursos 1 - 20 de 271

  1. Erratum to: MSRE-HTPrimer: a high-throughput and genome-wide primer design pipeline optimized for epigenetic research

    Pandey, Ram Vinay; Pulverer, Walter; Kallmeyer, Rainer; Beikircher, Gabriel; Pabinger, Stephan; Kriegner, Albert; Weinhäusel, Andreas

  2. Tobacco smoking differently influences cell types of the innate and adaptive immune system—indications from CpG site methylation

    Bauer, Mario; Fink, Beate; Thürmann, Loreen; Eszlinger, Markus; Herberth, Gunda; Lehmann, Irina

  3. Genome-wide DNA methylation profiling with MeDIP-seq using archived dried blood spots

    Staunstrup, Nicklas H.; Starnawska, Anna; Nyegaard, Mette; Christiansen, Lene; Nielsen, Anders L.; Børglum, Anders; Mors, Ole

  4. Increased global placental DNA methylation levels are associated with gestational diabetes

    Reichetzeder, C.; Dwi Putra, S. E.; Pfab, T.; Slowinski, T.; Neuber, C.; Kleuser, B.; Hocher, B.

  5. Next-generation sequencing methylation profiling of subjects with obesity identifies novel gene changes

    Day, Samantha E.; Coletta, Richard L.; Kim, Joon Young; Campbell, Latoya E.; Benjamin, Tonya R.; Roust, Lori R.; De Filippis, Elena A.; Dinu, Valentin; Shaibi, Gabriel Q.; Mandarino, Lawrence J.; Coletta, Dawn K.

  6. Studying epigenetic complexes and their inhibitors with the proteomics toolbox

    Weigt, David; Hopf, Carsten; Médard, Guillaume
    Some epigenetic modifier proteins have become validated clinical targets. With a few small molecule inhibitors already approved by national health administrations and many more in the pharmaceutical industry pipelines, there is a need for technologies that can promote full comprehension of the molecular action of these drugs. Proteomics, with its relatively unbiased nature, can contribute to a thorough understanding of the complexity of the megadalton complexes, which write, read and erase the histone code, and it can help study the on-target and off-target effect of the drugs designed to modulate their action. This review on the one hand gathers the...

  7. Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas

    Lim, Annette M.; Wong, Nicholas C.; Pidsley, Ruth; Zotenko, Elena; Corry, June; Dobrovic, Alexander; Clark, Susan J.; Rischin, Danny; Solomon, Benjamin

  8. Recent developments on the role of epigenetics in obesity and metabolic disease

    van Dijk, Susan J.; Tellam, Ross L.; Morrison, Janna L.; Muhlhausler, Beverly S.; Molloy, Peter L.
    The increased prevalence of obesity and related comorbidities is a major public health problem. While genetic factors undoubtedly play a role in determining individual susceptibility to weight gain and obesity, the identified genetic variants only explain part of the variation. This has led to growing interest in understanding the potential role of epigenetics as a mediator of gene-environment interactions underlying the development of obesity and its associated comorbidities. Initial evidence in support of a role of epigenetics in obesity and type 2 diabetes mellitus (T2DM) was mainly provided by animal studies, which reported epigenetic changes in key metabolically important tissues...

  9. PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns

    Côté, Sandra; Gagné-Ouellet, Valérie; Guay, Simon-Pierre; Allard, Catherine; Houde, Andrée-Anne; Perron, Patrice; Baillargeon, Jean-Patrice; Gaudet, Daniel; Guérin, Renée; Brisson, Diane; Hivert, Marie-France; Bouchard, Luigi

  10. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

    Diesch, Jeannine; Zwick, Anabel; Garz, Anne-Kathrin; Palau, Anna; Buschbeck, Marcus; Götze, Katharina S.
    The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. Based on their capacity to interfere with the DNA methylation machinery, these drugs are also referred to as hypomethylating agents (HMAs). As DNA methylation contributes to epigenetic regulation, azanucleosides are further considered to be among the first true “epigenetic drugs” that have reached clinical application. However, intriguing new evidence suggests that DNA hypomethylation is not the only mechanism of action for...

  11. Genome-wide placental DNA methylation analysis of severely growth-discordant monochorionic twins reveals novel epigenetic targets for intrauterine growth restriction

    Roifman, Maian; Choufani, Sanaa; Turinsky, Andrei L.; Drewlo, Sascha; Keating, Sarah; Brudno, Michael; Kingdom, John; Weksberg, Rosanna

  12. Two maternal duplications involving the CDKN1C gene are associated with contrasting growth phenotypes

    Boonen, Susanne Eriksen; Freschi, Andrea; Christensen, Rikke; Valente, Federica Maria; Lildballe, Dorte Launholt; Perone, Lucia; Palumbo, Orazio; Carella, Massimo; Uldbjerg, Niels; Sparago, Angela; Riccio, Andrea; Cerrato, Flavia

  13. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials

    Yun, Seongseok; Vincelette, Nicole D.; Abraham, Ivo; Robertson, Keith D.; Fernandez-Zapico, Martin E.; Patnaik, Mrinal M.

  14. Combined clinical and genetic testing algorithm for cervical cancer diagnosis

    Liou, Yu-Ligh; Zhang, Tao-Lan; Yan, Tian; Yeh, Ching-Tung; Kang, Ya-Nan; Cao, Lanqin; Wu, Nayiyuan; Chang, Chi-Feng; Wang, Huei-Jen; Yen, Carolyn; Chu, Tang-Yuan; Zhang, Yi; Zhang, Yu; Zhou, Honghao

  15. Amnion as a surrogate tissue reporter of the effects of maternal preeclampsia on the fetus

    Suzuki, Masako; Maekawa, Ryo; Patterson, Nicole E.; Reynolds, David M.; Calder, Brent R.; Reznik, Sandra E.; Heo, Hye J.; Einstein, Francine Hughes; Greally, John M.

  16. Peripheral blood methylation profiling of female Crohn’s disease patients

    Li Yim, Andrew Y. F.; Duijvis, Nicolette W.; Zhao, Jing; de Jonge, Wouter J.; D’Haens, Geert R. A. M.; Mannens, Marcel M. A. M.; Mul, Adri N. P. M.; te Velde, Anje A.; Henneman, Peter

  17. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort

    Perna, Laura; Zhang, Yan; Mons, Ute; Holleczek, Bernd; Saum, Kai-Uwe; Brenner, Hermann

  18. Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer

    Gao, Yang; Jones, Allison; Fasching, Peter A.; Ruebner, Matthias; Beckmann, Matthias W.; Widschwendter, Martin; Teschendorff, Andrew E.

  19. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background

    Gall Trošelj, Koraljka; Novak Kujundzic, Renata; Ugarkovic, Djurdjica
    When assembled in multiprotein polycomb repressive complexes (PRCs), highly evolutionary conserved polycomb group (PcG) proteins epigenetically control gene activity. Although the composition of PRCs may vary considerably, it is well established that the embryonic ectoderm development (EED) 1, suppressor of zeste (SUZ) 12, and methyltransferase enhancer of zeste (EZH2)-containing complex, PRC2, which is abundant in highly proliferative cells (including cancer cells), establishes a repressive methylation mark on histone 3 (H3K27me3). From the perspective of molecular cancer pathogenesis, this effect, when directed towards a promoter of tumor suppressor genes, represents pro-tumorigenic effect. This mode of action was shown in several cancer...

  20. Histone acetyltransferases: challenges in targeting bi-substrate enzymes

    Wapenaar, Hannah; Dekker, Frank J.
    Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins. Several HAT inhibitors, like bi-substrate inhibitors, natural product derivatives, small molecules, and protein–protein interaction inhibitors, have been developed. Despite their potential, a large gap remains between the biological activity of inhibitors in in vitro studies and their potential use as therapeutic agents. To bridge this gap, new...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.